Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LK-44
- Development stage
- Unknown
- Lead developer
- Guangdong Pharmaceutical University
01
Overview
LK-44: sourced facts only. name: "Following screening of the in-house library, the lead compound 01 was identified with potent inhibition on hCES2A, which was further optimized to obtain LK-44 with potent inhibitory activity (IC50 = 5.02 ± 0.67 μM) and high selectivity on hCES2A." [PMID:37300962]; target: "Following screening of the in-house library, the lead compound 01 was identified with potent inhibition on hCES2A, which was further optimized to obtain LK-44 with potent inhibitory activity (IC50 = 5.02 ± 0.67 μM) and high selectivity on hCES2A." [PMID:37300962]; developer: "School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China." [PMID:37300962]; stage: "Importantly, in vivo studies showed that LK-44 significantly reduced the side effects of irinotecan-induced diarrhea." [PMID:37300962]
02
Targets
CES2 (Carboxylesterase 2)
Beyond the preview
Go deeper on LK-44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LK-44.